PedAM
Pediatric Disease Annotations & Medicines
| Disease | cystic fibrosis |
| Symptom | |infection |
| Sentences | 128 |
| PubMedID- 25221853 | Purpose of review: newer 'innovative' formulations of antibiotics for pseudomonas aeruginosa lung infection in patients with cystic fibrosis include colistimethate sodium and tobramycin in the form of dry powders for inhalation (dpis). |
| PubMedID- 25742660 | Mycobacterium abscessus specific t-cells were detected in the blood of cystic fibrosis patients with confirmed chronic infection and a subgroup of patients without evidence of mycobacterium abscessus infection. |
| PubMedID- 21297072 | Aeruginosa during infection of patients with cystic fibrosis, and provide in vivo evidence for a link between pyocyanin production and patient morbidity. |
| PubMedID- 23403223 | Abscessus lung infection in patients with cystic fibrosis. |
| PubMedID- 22762867 | Comparison of two treatment regimens for eradication of pseudomonas aeruginosa infection in children with cystic fibrosis. |
| PubMedID- 23375733 | Prevalence of helicobacter pylori infection in patients with cystic fibrosis. |
| PubMedID- 22330747 | Caveolin 2, which localizes to the golgi complex but redistributes to plasma membrane, caveolae and rafts when co-expressed with caveolin 1, is a potential key molecule related to the pseudomonas infection causing pneumonia in patients with cystic fibrosis and other immunocompromising conditions . |
| PubMedID- 26238926 | Pulmonary mycobacterium abscessus sensu lato infection in patients without cystic fibrosis. |
| PubMedID- 26300961 | Relative to the reference antibiotic gentamicin, the polyamide 54 exhibited comparable antibacterial activity against gram negative bacteria (p. aeruginosa); the most common pathogen causing chronic infection in people with cystic fibrosis. |
| PubMedID- 24515341 | Authors' conclusions: we were unable to identify any randomised controlled trials or quasi-randomised controlled trials on the efficacy of neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. |
| PubMedID- 23030647 | During the last decades it has emerged as a cause of chronic pulmonary infection in patients with cystic fibrosis (cf). |
| PubMedID- 20218338 | Identification of possible mechanisms of lung infection in patients with cystic fibrosis will allow to develop evidence-based system of prevention of infectious complications in these patients. |
| PubMedID- 24232573 | Samples from wound infections and lungs of patients with cystic fibrosis often contains both p. aeruginosa and s. aureus, underscoring the clinical importance of co-infection by these two bacteria.24,25 it has been shown that interaction of p. aeruginosa and gram-positive bacteria including s. aureus can lead to increased virulence in p. aeruginosa.26 there is little information available about the interaction between these two bacterial pathogens and the importance of this interaction with regards to the severity and outcome of infection. |
| PubMedID- 23984384 | However, the most serious medical problem caused by p. aeruginosa is lung infection associated with cystic fibrosis 3. |
| PubMedID- 24064077 | Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis. |
| PubMedID- 24489509 | Treatment of pseudomonas and staphylococcus bronchopulmonary infection in patients with cystic fibrosis. |
| PubMedID- 23504071 | Indeed, such a strategy has recently been reported to discover a gene that impacts pseudomonas infection in individuals with cystic fibrosis (emond et al. |
| PubMedID- 24439251 | Dermatitidis triggers antibody production and may cause significant airway infection in patients with cystic fibrosis. |
| PubMedID- 20105324 | Background: staphylococcus aureus infection in patients with cystic fibrosis (cf) is frequent and may be due to colonization by a few pathogenic lineages. |
| PubMedID- 20019078 | Genetic adaptation of pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in muca and/or lasr mutants. |
| PubMedID- 22336832 | Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. |
| PubMedID- 25705428 | In the last decade, many studies published the use of colistin in the treatment of lung infection in patients without cystic fibrosis, with conflicting results. |
| PubMedID- 20185551 | A coordinated approach has been used to measure the fitness of bcc bacteria isolated from cystic fibrosis (cf) patients with chronic bcc infection using methods relevant to bcc growth and survival conditions. |
| PubMedID- 24091166 | Background: inhaled tobramycin therapy has been shown to be efficacious in clinical trials for the eradication of initial pseudomonas aeruginosa infection in children with cystic fibrosis (cf). |
| PubMedID- 24464974 | Introduction: aerosolized tobramycin is a standard of care for chronic pseudomonas aeruginosa (pa) infection in patients with cystic fibrosis (cf). |
| PubMedID- 24522146 | Tobramycin powder for inhalation (tobi podhaler or tip) is approved for the treatment of pseudomonas aeruginosa airway infection in patients with cystic fibrosis (cf). |
| PubMedID- 21977035 | There have been a number of studies demonstrating p. aeruginosa cross-infection between patients with cystic fibrosis . |
| PubMedID- 25443661 | Nocardia farcinica lung infection in a patient with cystic fibrosis and a lung transplant. |
| PubMedID- 24766052 | Chronic pulmonary pseudomonal infection in patients with cystic fibrosis: a model for early phase symbiotic evolution. |
| PubMedID- 21494150 | Purpose of review: lung disease in cystic fibrosis (cf) results from chronic airway infection and inflammation leading to progressive bronchiectasis and respiratory failure. |
| PubMedID- 20941680 | Conclusion: ecmo is a another treatment option for serious ards in infection-related worsening of pulmonary cystic fibrosis. |
| PubMedID- 22563440 | This is the first prospective randomized controlled clinical trial to explore whether treatment of chronic a. fumigatus airway infection in patients with cystic fibrosis provides clinical benefits. |
| PubMedID- 21893650 | Comparative efficacy and safety of 4 randomized regimens to treat early pseudomonas aeruginosa infection in children with cystic fibrosis. |
| PubMedID- 20166098 | Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. |
| PubMedID- 23701325 | Why is pseudomonas aeruginosa a common cause of infection in individuals with cystic fibrosis. |
| PubMedID- 21545738 | Abscessus infection was associated with cystic fibrosis and m. |
| PubMedID- 20503281 | Pseudomonas aeruginosa (psa) is the most common pathogen to cause chronic lung infection in children with cystic fibrosis (cf), and is associated with an increase in both morbidity and mortality. |
| PubMedID- 25830686 | Maltophilia lung infection in patients with cystic fibrosis. |
| PubMedID- 26517580 | Neutrophil-associated inflammation during pseudomonas aeruginosa lung infection is a determinant of morbidity in cystic fibrosis (cf). |
| PubMedID- 24031589 | Pseudomonas aeruginosa is a common cause of chronic pulmonary infection in patients with cystic fibrosis (cf). |
| PubMedID- 20211000 | Nocardia farcinica lung infection in a patient with cystic fibrosis: a case report. |
| PubMedID- 21833328 | P. aeruginosa is also the most common cause of chronic airway infection in individuals with cystic fibrosis (cf). |
| PubMedID- 22401602 | Challenges with current inhaled treatments for chronic pseudomonas aeruginosa infection in patients with cystic fibrosis. |
| PubMedID- 25658563 | Species of the burkholderia cepacia complex are associated with opportunistic infection in patients with cystic fibrosis. |
| PubMedID- 24614401 | We used antibiotic therapy of chronic lung infection in persons with cystic fibrosis as a model system to assess the influence of key variables of therapy on measures of microbial community perturbation. |
| PubMedID- 25815200 | 2010 dabigatranprevention of stroke or systemic embolism in patients with non-valvular atrial fibrillationboehringer ingelheim pty ltdpbsfinancially-basedpublic summary document atomoxetine hydrochlorideadhd diagnosed between the ages of 6 and 18 yearseli lilly australia pty ltdpbsfinancially-basedpublic summary document fingolimodrrmsnovartis pharmaceuticals australia pty ltdpbsfinancially-based; outcome-basedpublic summary document cinacalcet hydrochlorideend stage renal disease receiving dialysis who have uncontrolled secondary hyperparathyroidismamgen australia pty ltdpbsfinancially-basedpbs schedule , public summary document clostridium botulinum type a toxin-haemagglutinin complexsevere spasticity of the upper limb in adults following a stroke, as an adjunct to physical therapyipsen pty ltdpbsfinancially-basedpublic summary document fentanyl citratefentanyl lozenges for the treatment of breakthrough painorphan australia pty ltdpbsfinancially-basedpublic summary document natalizumabrrmsbiogen idec australia pty ltdpbsfinancially-basedpublic summary document paliperidoneschizophreniajanssen-cilag pty ltdpbsfinancially-basedpublic summary document botulinum toxin type a purified neurotoxin complexmoderate to severe spasticity of the upper limb in adults following a stroke as an adjunct to physical therapyallergan australia pty ltdpbsfinancially-basedpublic summary document tenofovir disoproxil fumaratetreatment of chronic hepatitis bgilead sciences pty ltdpbsfinancially-basedpublic summary document pramipexole hydrochlorideidiopathic parkinson diseaseboehringer ingelheim pty ltdpbsfinancially-basedpublic summary document tobramycinpseudomonas aeruginosa respiratory infection in a patient with cystic fibrosisnovartis pharmaceuticals australia pty ltdpbsfinancially-basedpublic summary document ticagreloracs, mi, or unstable anginaastrazeneca pty ltdpbsfinancially-basedpublic summary document pregabalinneuropathic painpfizer australia pty ltdpbsfinancially-basedpublic summary document rivaroxabanacute symptomatic dvtbayer australia ltdpbsfinancially-basedpublic summary document aztreonampseudomonas aeruginosa infection in patients with cystic fibrosisgilead sciences pty ltdpbsfinancially-basedpublic summary document crinone (progesterone gel)supplement progesterone in women who have luteal phase defectmerck seronopbsfinancially-basedrobertson et al. |
| PubMedID- 26268854 | The opportunistic pathogen pseudomonas aeruginosa causes chronic lung infection in patients with cystic fibrosis. |
| PubMedID- 22717532 | Objective: to examine the incidence of recurrent clostridium difficile infection in patients with cystic fibrosis (cf), including patients who had undergone lung transplantation, and review clinical findings in hospitalized patients with c. |
| PubMedID- 20504347 | Other reports suggest that bacterial infection associated with cystic fibrosis induces metaplastic bone replacement, as well as the destruction and elimination of the bronchial cartilage 9. |
| PubMedID- 20146956 | Nocardia farcinica infection in a patient with cystic fibrosis. |